Reference health

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

https://doi.org/10.1038/nm1763
CiteStamped reference-health badge
48/48 checkable references clean · checked 2026-07-23

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 48 checked references that resolve
resolves10.1038/ni0901-764
Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity
resolves10.1056/NEJM199406303302608
Systemic Lupus Erythematosus
resolves10.1084/jem.126.1.109
RESISTANCE OF LONG-LIVED LYMPHOCYTES AND PLASMA CELLS IN RAT LYMPH NODES TO TREATMENT WITH PREDNISONE, CYCLOPHOSPHAMIDE, 6-MERCAPTOPURINE, AND ACTINOMYCIN D
resolves10.1016/S0952-7915(98)80162-3
Long-lived plasma cells: a mechanism for maintaining persistent antibody production
resolves10.1182/blood.V89.12.4646
Persistence of Antibody to Human Parvovirus B19 After Allogeneic Bone Marrow Transplantation: Role of Prior Recipient Immunity
resolves10.1182/blood.V87.2.818.bloodjournal872818
The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation
resolves10.1016/S0065-2776(08)60342-9
Murine Models of Systemic Lupus Erythematosus
resolves10.1084/jem.20040168
Short-lived Plasmablasts and Long-lived Plasma Cells Contribute to Chronic Humoral Autoimmunity in NZB/W Mice
resolves10.1146/annurev.immunol.23.021704.115723
MAINTENANCE OF SERUM ANTIBODY LEVELS
resolves10.1038/nrc1361
The proteasome: a suitable antineoplastic target
resolves10.1200/JCO.2005.11.030
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
resolves10.1158/0008-5472.CAN-06-2258
Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition
resolves10.1182/blood-2005-08-3531
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
resolves10.1002/eji.1830160206
Limiting dilution analysis of the B cell compartment in human bone marrow
resolves10.1002/art.1780390605
Review: Nephritogenic autoantibodies in lupus: Current concepts and continuing controversies
resolves10.1056/NEJM199805073381906
Antibodies to DNA
resolves10.1038/40540
Lifetime of plasma cells in the bone marrow
resolves10.1038/nri1886
Competence and competition: the challenge of becoming a long-lived plasma cell
resolves10.1182/blood-2005-08-3494
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
resolves10.1038/sj.leu.2404734
Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells
resolves10.1038/sj.cdd.4401373
Roles of CHOP/GADD153 in endoplasmic reticulum stress
resolves10.4049/jimmunol.179.1.195
Synergism between NF-κB1/p50 and Notch2 during the Development of Marginal Zone B Lymphocytes
resolves10.1016/j.immuni.2006.04.005
Canonical NF-κB Activity, Dispensable for B Cell Development, Replaces BAFF-Receptor Signals and Promotes B Cell Proliferation upon Activation
resolves10.1038/sj.cdd.4402297
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development
resolves10.1038/35008096
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
resolves10.1074/jbc.M205011200
Activation of an Unfolded Protein Response during Differentiation of Antibody-secreting B Cells
resolves10.1038/ni907
Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1
resolves10.1101/gad.13.10.1211
Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls
resolves10.1016/S0955-0674(00)00219-2
Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals
resolves10.1038/35085509
Plasma cell differentiation requires the transcription factor XBP-1
resolves10.1016/S1074-7613(03)00024-4
Sequential Waves of Functionally Related Proteins Are Expressed When B Cells Prepare for Antibody Secretion
resolves10.1038/384432a0
Sec6l-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction
resolves10.1007/s10495-005-3088-0
Role of the unfolded protein response in cell death
resolves10.1158/0008-5472.CAN-05-2394
Bortezomib Inhibits PKR-Like Endoplasmic Reticulum (ER) Kinase and Induces Apoptosis via ER Stress in Human Pancreatic Cancer Cells
resolves10.1158/0008-5472.CAN-05-2370
Bortezomib Sensitizes Pancreatic Cancer Cells to Endoplasmic Reticulum Stress-Mediated Apoptosis
resolves10.1016/j.molimm.2006.08.021
VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF
resolves10.1016/j.immuni.2004.05.001
Cellular Niches Controlling B Lymphocyte Behavior within Bone Marrow during Development
resolves10.1111/j.1600-065X.1995.tb00069.x
Inquiry into Murine and Human Lupus
resolves10.1172/JCI108626
Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis.
resolves10.1002/art.22211
B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles
resolves10.1002/art.20858
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down‐regulation of the T cell costimulatory molecule CD40 ligand: An open‐label trial
resolves10.1002/art.10541
An open study of B lymphocyte depletion in systemic lupus erythematosus
resolves10.1002/art.21778
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
resolves10.1002/art.20430
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab
resolves10.1182/blood.V99.6.2154
The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression
resolves10.1016/B978-0-12-442702-0.50020-0
Induction of Antibody Formation In Mouse Bone Marrow
resolves10.1093/intimm/13.12.1461
An Ig μ-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB × NZW)F1 mice
The 1 reference without a DOI — listed, not checked
no DOI — not checkedHideshima, T., Richardson, P.G. & Anderson, K.C. Targeting proteasome inhibition in hematologic malignancies. Rev. Clin. Exp. Hematol. 7, 191–204 (2003).
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1038/nm1763"><img src="https://citestamp.com/citestamped/10.1038/nm1763/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1038/nm1763/badge.svg)](https://citestamp.com/citestamped/10.1038/nm1763)